Tocagen (TOCA) IPO Opens Modestly Higher

Today's IPO for Tocagen Inc. (Nasdaq: TOCA) opened for trading at $10.27 after pricing 8,500,000 shares of common stock at a public offering price of $10.00 per share.

Leerink Partners LLC, Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated are acting as joint bookrunning managers for the offering.

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer. Tocagen is developing its lead product candidate, Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC).

You May Also Be Interested In